These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 32281456)

  • 21. The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease.
    Hong YD; Onukwugha E; Slejko JF
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1353-1362. PubMed ID: 32996389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance.
    Soliman AM; Surrey ES; Bonafede M; Nelson JK; Vora JB; Agarwal SK
    J Manag Care Spec Pharm; 2019 May; 25(5):566-572. PubMed ID: 31039061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
    Meyers J; Yu Y; Kaye JA; Davis KL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
    Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health care resource utilization and costs of recurrent
    Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
    J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis.
    Almony A; Keyloun KR; Shah-Manek B; Multani JK; McGuiness CB; Chen CC; Campbell JH
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1260-1272. PubMed ID: 34464210
    [No Abstract]   [Full Text] [Related]  

  • 27. Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States.
    Blaiss MS; Meadows JA; Yu S; Robison DR; Hass SL; Norrett KE; Guerin A; Latremouille-Viau D; Tilles SA
    J Manag Care Spec Pharm; 2021 Apr; 27(4):516-527. PubMed ID: 33470880
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United States.
    Thayer S; Bell C; McDonald CM
    J Manag Care Spec Pharm; 2017 Jun; 23(6):633-641. PubMed ID: 28530521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
    Muffly L; Young C; Feng Q; Nimke D; Pandya BJ
    Leuk Lymphoma; 2023; 64(11):1832-1839. PubMed ID: 37486091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health Care Burden Associated with Outpatient Opioid Use Following Inpatient or Outpatient Surgery.
    Brummett CM; England C; Evans-Shields J; Kong AM; Lew CR; Henriques C; Zimmerman NM; Pawasauskas J; Oderda G
    J Manag Care Spec Pharm; 2019 Sep; 25(9):973-983. PubMed ID: 31313621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
    Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
    J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis.
    Guo A; Niyazov A; Macaulay D; Terasawa E; Schmerold L; Wu EQ; Krieger S
    J Manag Care Spec Pharm; 2017 Jul; 23(7):771-780. PubMed ID: 28650249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
    Luskin AT; Antonova EN; Broder MS; Chang E; Raimundo K; Solari PG
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients.
    Grabner M; Strati E; Sandman K; Forsythe A
    J Manag Care Spec Pharm; 2021 May; 27(5):607-614. PubMed ID: 33908282
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
    Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic Burden of Illness in Adult Patients with Nocturia.
    Dmochowski R; Brucker BM; Cole E; Kawahara S; Pulicharam R; Burk C; Tung A; Hale D
    J Manag Care Spec Pharm; 2019 May; 25(5):593-604. PubMed ID: 30675816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
    Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
    [No Abstract]   [Full Text] [Related]  

  • 40. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
    Margolis J; Barron JJ; Grochulski WD
    J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.